Inhibition of RACK1‐Mediated NLRP3 Oligomerization (Active Conformation) Ameliorates Acute Respiratory Distress Syndrome
Abstract Aberrant activation of the NACHT, LRR, and PYD domain‐containing protein 3 (NLRP3) inflammasome contributes to the pathogenesis of fatal and perplexing pulmonary diseases. Although pharmacological inhibition of the NLRP3 inflammasome brings potent therapeutic effects in clinical trials and...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202411355 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849318248338685952 |
|---|---|
| author | Jian Cui Meng Yang Chengli Yu Haidong Zhang Yuan Gong Yang Hu Yue Wang Qingxin Yuan An Pan Jiepin Li Yaowen Hu Zecheng Jin Xuemei Peng Anyuan Wu Junwei Wang Qian Wang Yinan Zhang Lihong Hu |
| author_facet | Jian Cui Meng Yang Chengli Yu Haidong Zhang Yuan Gong Yang Hu Yue Wang Qingxin Yuan An Pan Jiepin Li Yaowen Hu Zecheng Jin Xuemei Peng Anyuan Wu Junwei Wang Qian Wang Yinan Zhang Lihong Hu |
| author_sort | Jian Cui |
| collection | DOAJ |
| description | Abstract Aberrant activation of the NACHT, LRR, and PYD domain‐containing protein 3 (NLRP3) inflammasome contributes to the pathogenesis of fatal and perplexing pulmonary diseases. Although pharmacological inhibition of the NLRP3 inflammasome brings potent therapeutic effects in clinical trials and preclinical models, the molecular chaperones and transition governing its transformation from an auto‐suppressed state to an active oligomer remain controversial. Here, this work shows that sesquiterpene bigelovin inhibited NLRP3 inflammasome activation and downstream pro‐inflammatory cytokines release via canonical, noncanonical, and alternative pathways at nanomolar ranges. Chemoproteomic target identification discloses that bigelovin covalently bound to Cys168 of RACK1, disrupting the interaction between RACK1 and NLRP3 monomer and thereby suppressing NLRP3 inflammasome oligomerization in vitro and in vivo. Bigelovin treatment significantly alleviates the severity of NLRP3‐related pulmonary disorders in murine models, such as LPS‐induced ARDS and silicosis. These results consolidated the intricate role of RACK1 in transiting the NLRP3 state and provided a new anti‐inflammatory lead and therapy for NLRP3‐driven diseases. |
| format | Article |
| id | doaj-art-817c72cb997e44e29db4c5241ea88bcd |
| institution | Kabale University |
| issn | 2198-3844 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advanced Science |
| spelling | doaj-art-817c72cb997e44e29db4c5241ea88bcd2025-08-20T03:50:58ZengWileyAdvanced Science2198-38442025-07-011227n/an/a10.1002/advs.202411355Inhibition of RACK1‐Mediated NLRP3 Oligomerization (Active Conformation) Ameliorates Acute Respiratory Distress SyndromeJian Cui0Meng Yang1Chengli Yu2Haidong Zhang3Yuan Gong4Yang Hu5Yue Wang6Qingxin Yuan7An Pan8Jiepin Li9Yaowen Hu10Zecheng Jin11Xuemei Peng12Anyuan Wu13Junwei Wang14Qian Wang15Yinan Zhang16Lihong Hu17Jiangsu Key Laboratory for Functional Substance of Chinese Medicine Stake Key Laboratory Cultivation Base for TCM Quality and Efficacy School of Pharmacy Nanjing University of Chinese Medicine Nanjing 210023 ChinaJiangsu Key Laboratory for Functional Substance of Chinese Medicine Stake Key Laboratory Cultivation Base for TCM Quality and Efficacy School of Pharmacy Nanjing University of Chinese Medicine Nanjing 210023 ChinaJiangsu Key Laboratory for Functional Substance of Chinese Medicine Stake Key Laboratory Cultivation Base for TCM Quality and Efficacy School of Pharmacy Nanjing University of Chinese Medicine Nanjing 210023 ChinaDepartment of Respiratory Medicine Affiliated Hospital of Nanjing University of Chinese Medicine Jiangsu Province Hospital of Chinese Medicine Nanjing Jiangsu 210029 ChinaJiangsu Key Laboratory for Functional Substance of Chinese Medicine Stake Key Laboratory Cultivation Base for TCM Quality and Efficacy School of Pharmacy Nanjing University of Chinese Medicine Nanjing 210023 ChinaJiangsu Key Laboratory for Functional Substance of Chinese Medicine Stake Key Laboratory Cultivation Base for TCM Quality and Efficacy School of Pharmacy Nanjing University of Chinese Medicine Nanjing 210023 ChinaJiangsu Key Laboratory for Functional Substance of Chinese Medicine Stake Key Laboratory Cultivation Base for TCM Quality and Efficacy School of Pharmacy Nanjing University of Chinese Medicine Nanjing 210023 ChinaJiangsu Key Laboratory for Functional Substance of Chinese Medicine Stake Key Laboratory Cultivation Base for TCM Quality and Efficacy School of Pharmacy Nanjing University of Chinese Medicine Nanjing 210023 ChinaJiangsu Key Laboratory for Functional Substance of Chinese Medicine Stake Key Laboratory Cultivation Base for TCM Quality and Efficacy School of Pharmacy Nanjing University of Chinese Medicine Nanjing 210023 ChinaDepartment of Respiratory Medicine Affiliated Hospital of Nanjing University of Chinese Medicine Jiangsu Province Hospital of Chinese Medicine Nanjing Jiangsu 210029 ChinaJiangsu Key Laboratory for Functional Substance of Chinese Medicine Stake Key Laboratory Cultivation Base for TCM Quality and Efficacy School of Pharmacy Nanjing University of Chinese Medicine Nanjing 210023 ChinaJiangsu Key Laboratory for Functional Substance of Chinese Medicine Stake Key Laboratory Cultivation Base for TCM Quality and Efficacy School of Pharmacy Nanjing University of Chinese Medicine Nanjing 210023 ChinaJiangsu Key Laboratory for Functional Substance of Chinese Medicine Stake Key Laboratory Cultivation Base for TCM Quality and Efficacy School of Pharmacy Nanjing University of Chinese Medicine Nanjing 210023 ChinaJiangsu Key Laboratory for Functional Substance of Chinese Medicine Stake Key Laboratory Cultivation Base for TCM Quality and Efficacy School of Pharmacy Nanjing University of Chinese Medicine Nanjing 210023 ChinaJiangsu Key Laboratory for Functional Substance of Chinese Medicine Stake Key Laboratory Cultivation Base for TCM Quality and Efficacy School of Pharmacy Nanjing University of Chinese Medicine Nanjing 210023 ChinaDepartment of Respiratory Medicine Affiliated Hospital of Nanjing University of Chinese Medicine Jiangsu Province Hospital of Chinese Medicine Nanjing Jiangsu 210029 ChinaJiangsu Key Laboratory for Functional Substance of Chinese Medicine Stake Key Laboratory Cultivation Base for TCM Quality and Efficacy School of Pharmacy Nanjing University of Chinese Medicine Nanjing 210023 ChinaJiangsu Key Laboratory for Functional Substance of Chinese Medicine Stake Key Laboratory Cultivation Base for TCM Quality and Efficacy School of Pharmacy Nanjing University of Chinese Medicine Nanjing 210023 ChinaAbstract Aberrant activation of the NACHT, LRR, and PYD domain‐containing protein 3 (NLRP3) inflammasome contributes to the pathogenesis of fatal and perplexing pulmonary diseases. Although pharmacological inhibition of the NLRP3 inflammasome brings potent therapeutic effects in clinical trials and preclinical models, the molecular chaperones and transition governing its transformation from an auto‐suppressed state to an active oligomer remain controversial. Here, this work shows that sesquiterpene bigelovin inhibited NLRP3 inflammasome activation and downstream pro‐inflammatory cytokines release via canonical, noncanonical, and alternative pathways at nanomolar ranges. Chemoproteomic target identification discloses that bigelovin covalently bound to Cys168 of RACK1, disrupting the interaction between RACK1 and NLRP3 monomer and thereby suppressing NLRP3 inflammasome oligomerization in vitro and in vivo. Bigelovin treatment significantly alleviates the severity of NLRP3‐related pulmonary disorders in murine models, such as LPS‐induced ARDS and silicosis. These results consolidated the intricate role of RACK1 in transiting the NLRP3 state and provided a new anti‐inflammatory lead and therapy for NLRP3‐driven diseases.https://doi.org/10.1002/advs.202411355ARDSbigelovinNLRP3 inflammasomeRACK1 |
| spellingShingle | Jian Cui Meng Yang Chengli Yu Haidong Zhang Yuan Gong Yang Hu Yue Wang Qingxin Yuan An Pan Jiepin Li Yaowen Hu Zecheng Jin Xuemei Peng Anyuan Wu Junwei Wang Qian Wang Yinan Zhang Lihong Hu Inhibition of RACK1‐Mediated NLRP3 Oligomerization (Active Conformation) Ameliorates Acute Respiratory Distress Syndrome Advanced Science ARDS bigelovin NLRP3 inflammasome RACK1 |
| title | Inhibition of RACK1‐Mediated NLRP3 Oligomerization (Active Conformation) Ameliorates Acute Respiratory Distress Syndrome |
| title_full | Inhibition of RACK1‐Mediated NLRP3 Oligomerization (Active Conformation) Ameliorates Acute Respiratory Distress Syndrome |
| title_fullStr | Inhibition of RACK1‐Mediated NLRP3 Oligomerization (Active Conformation) Ameliorates Acute Respiratory Distress Syndrome |
| title_full_unstemmed | Inhibition of RACK1‐Mediated NLRP3 Oligomerization (Active Conformation) Ameliorates Acute Respiratory Distress Syndrome |
| title_short | Inhibition of RACK1‐Mediated NLRP3 Oligomerization (Active Conformation) Ameliorates Acute Respiratory Distress Syndrome |
| title_sort | inhibition of rack1 mediated nlrp3 oligomerization active conformation ameliorates acute respiratory distress syndrome |
| topic | ARDS bigelovin NLRP3 inflammasome RACK1 |
| url | https://doi.org/10.1002/advs.202411355 |
| work_keys_str_mv | AT jiancui inhibitionofrack1mediatednlrp3oligomerizationactiveconformationamelioratesacuterespiratorydistresssyndrome AT mengyang inhibitionofrack1mediatednlrp3oligomerizationactiveconformationamelioratesacuterespiratorydistresssyndrome AT chengliyu inhibitionofrack1mediatednlrp3oligomerizationactiveconformationamelioratesacuterespiratorydistresssyndrome AT haidongzhang inhibitionofrack1mediatednlrp3oligomerizationactiveconformationamelioratesacuterespiratorydistresssyndrome AT yuangong inhibitionofrack1mediatednlrp3oligomerizationactiveconformationamelioratesacuterespiratorydistresssyndrome AT yanghu inhibitionofrack1mediatednlrp3oligomerizationactiveconformationamelioratesacuterespiratorydistresssyndrome AT yuewang inhibitionofrack1mediatednlrp3oligomerizationactiveconformationamelioratesacuterespiratorydistresssyndrome AT qingxinyuan inhibitionofrack1mediatednlrp3oligomerizationactiveconformationamelioratesacuterespiratorydistresssyndrome AT anpan inhibitionofrack1mediatednlrp3oligomerizationactiveconformationamelioratesacuterespiratorydistresssyndrome AT jiepinli inhibitionofrack1mediatednlrp3oligomerizationactiveconformationamelioratesacuterespiratorydistresssyndrome AT yaowenhu inhibitionofrack1mediatednlrp3oligomerizationactiveconformationamelioratesacuterespiratorydistresssyndrome AT zechengjin inhibitionofrack1mediatednlrp3oligomerizationactiveconformationamelioratesacuterespiratorydistresssyndrome AT xuemeipeng inhibitionofrack1mediatednlrp3oligomerizationactiveconformationamelioratesacuterespiratorydistresssyndrome AT anyuanwu inhibitionofrack1mediatednlrp3oligomerizationactiveconformationamelioratesacuterespiratorydistresssyndrome AT junweiwang inhibitionofrack1mediatednlrp3oligomerizationactiveconformationamelioratesacuterespiratorydistresssyndrome AT qianwang inhibitionofrack1mediatednlrp3oligomerizationactiveconformationamelioratesacuterespiratorydistresssyndrome AT yinanzhang inhibitionofrack1mediatednlrp3oligomerizationactiveconformationamelioratesacuterespiratorydistresssyndrome AT lihonghu inhibitionofrack1mediatednlrp3oligomerizationactiveconformationamelioratesacuterespiratorydistresssyndrome |